SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

DexCom's growth rate has been declining over multiple periods. The company expects as little as 1% organic growth for the current quarter.

NEW YORK CITY, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.

RADNOR, PA / ACCESSWIRE / August 8, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ:DXCM) ("DexCom"). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion.

DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop and a $750 million share repurchase. DexCom faces strong competition from Abbott, whose CGM devices appear more attractive to customers, particularly with the new Abbott-Medtronic partnership posing a significant challenge to DexCom's market share recovery efforts. Despite competitive concerns, DexCom's new OTC CGM device, Stelo, is expected to contribute to revenue growth, particularly as the OTC market is projected to reach $5.1 billion over the next.

DexCom and Pinterest delivered decent second-quarter results. However, their third-quarter projections were much less impressive.

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.

RADNOR, Pa. , Aug. 7, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) ("DexCom").